Key Takeaways Kymera Therapeutics (KYMR) shares surged over 40% to an all-time high Monday afternooon after the drugmaker reported positive results from an early test of an oral anti-inflammatory drug. The company said a Phase 1b trial of its KT-621 drug found it can help significantly reduce inflammation for patients with eczema and asthma. The treatment works by targeting STAT6, a protein that affects immune responses. CEO Nello Mainolfi said the results "exceeded our highest expectations and provide a po ...